HEMISPHERX BIOPHARMA, INC. (NYSEAMERICAN:HEB) Files An 8-K Regulation FD DisclosureItem 7.01. Regulation FD Disclosure.
On May 1, 2018, we issued a stockholder letter, a copy of which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information set forth herein is deemed to be “furnished” and shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
HEMISPHERX BIOPHARMA INC ExhibitEX-99.1 2 ex99-1.htm Exhibit 99.1 Dear Fellow Stockholders: As you probably know,…To view the full exhibit click here
About HEMISPHERX BIOPHARMA, INC. (NYSEAMERICAN:HEB)
Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company’s segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The Company’s products include Alferon N Injection and Ampligen. Alferon N Injection is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients of over 18 years of age. Ampligen is a drug undergoing clinical development for the treatment of Chronic Fatigue Syndrome (CFS). Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) is a low-dose, oral liquid formulation of natural alpha interferon. Alferon LDO is a liquid natural interferon for oral administration. HEMISPHERX BIOPHARMA, INC. (NYSEAMERICAN:HEB) Recent Trading Information
HEMISPHERX BIOPHARMA, INC. (NYSEAMERICAN:HEB) closed its last trading session up +0.003 at 0.325 with shares trading hands.